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ABSTRACT
The unrestrained proliferation of cancer cells requires a high level of ribosome 
biogenesis. The first stage of ribosome biogenesis is the transcription of the large 
ribosomal RNAs (rRNAs); the structural and functional components of the ribosome. 
Transcription of rRNA is carried out by RNA Polymerase I (Pol-I) and its associated 
holoenzyme complex. 
Here we report that BRCA1, a nuclear phosphoprotein, and a known tumour 
suppressor involved in variety of cellular processes such as DNA damage response, 
transcriptional regulation, cell cycle control and ubiquitylation, is associated with 
rDNA repeats, in particular with the regulatory regions of the rRNA gene. 
We demonstrate that BRCA1 interacts directly with the basal Pol-I transcription 
factors; upstream binding factor (UBF), selectivity factor-1 (SL1) as well as interacting 
with RNA Pol-I itself. We show that in response to DNA damage, BRCA1 occupancy 
at the rDNA repeat is decreased and the observed BRCA1 interactions with the Pol-I 
transcription machinery are weakened. 
We propose, therefore, that there is a rDNA associated fraction of BRCA1 involved 
in DNA damage dependent regulation of Pol-I transcription, regulating the stability 
and formation of the Pol-I holoenzyme during initiation and/or elongation in response 
to DNA damage.
INTRODUCTION
Ribosome biogenesis is a fundamental cellular 
process that is tightly regulated by an elaborate network 
of cellular signalling cascades which respond to a variety 
of intra- and extra-cellular stimuli [1–6]. The synthesis 
of ribosomal RNA (rRNA) by RNA polymerases I and 
III (Pol-I & Pol-III) drives ribosome biogenesis and is 
linked to cell growth and proliferation in eukaryotes 
[3, 4, 7, 8]. High levels of rRNA synthesis are essential 
in supporting the unrestrained proliferation of cancer 
cells, and rRNA transcription is now emerging as a novel 
target for anticancer therapy [9–13]. In normal cells rRNA 
synthesis is kept under tight control by various oncogenes 
and tumour suppressors including p53, Rb, C-MYC, 
Ppan, CKII and PTEN, and now it is evident that cancer 
cells have lost some of these restraints [2, 4, 14–17]. 
It is reasonable to hypothesise that pathways leading 
to upregulation of ribosome biogenesis are different 
in different types of malignant cells because different 
oncogenes and tumour suppressors are affected in different 
types of cancers. 
BRCA1 is 220 kDa nuclear phosphoprotein 
and known tumour suppressor which is involved in 
a variety of cellular processes such as DNA damage 
response, transcriptional regulation, cell cycle control 
and ubiquitylation [18–21]. Recently, BRCA1 has been 
shown to play the role of a general repressor of RNA 
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Polymerase III (Pol-III) [22] and in this role it represses 
transcription of tRNA and snRNA which are required for 
efficient cell proliferation. BRCA1 selectively regulates 
transcription of different genes by interacting with variety 
of polypeptides (for reviews see [23, 24]). BRCA1 is 
mutated in approximately 5–10% of hereditary breast 
cancers [25] and BRCA1 expression is downregulated in 
up to 40% of sporadic invasive breast carcinomas [26]. 
Therefore, BRCA1 dysfunction is a significant factor 
underpinning the development of both hereditary and 
sporadic breast cancers. 
In this study we have investigated the role of 
BRCA1 in the regulation of transcription of large 
ribosomal RNAs and selected ribosomal proteins in breast 
cancer cells. We have shown that BRCA1 is associated 
with the rDNA repeat and interacts with components of 
Pol-I transcription machinery. We demonstrate a positive 
regulatory role of BRCA1 in transcription of rRNA, but 
found no role for BRCA1 in the regulation of transcription 
of ribosomal proteins. We found that DNA damage 
affects both the BRCA1 association with the rDNA and 
interactions between BRCA1 and Pol-I factors. Together 
these data suggest that BRCA1 has novel regulatory 
functions in the control of Pol-I transcription and therefore 
ribosome biogenesis. 
RESULTS 
BRCA1 associates with rDNA repeat and  
co-localises with Pol-I
BRCA1 has been shown to be involved in the 
regulation of transcription by RNA Polymerases II and 
III by interacting with transcription factors and regulatory 
regions of particular genes [22, 27, 28]. We used chromatin 
immunoprecipitation (ChIP) to examine the association of 
BRCA1 with various regions of rDNA repeat (Figure 1A). 
Importantly, antibodies used in this work were previously 
validated and used in ChIP-seq experiments [29, 30], thus 
demonstrating sufficient level of specificity.
The level of BRCA1 protein is different in 
different cells (Supplementary Figure S1), but ChIP 
results demonstrate similarity in the occupancy levels 
and in the distribution profile of BRCA1 at rDNA repeat 
in all cell lines tested (Figure 1B). Consistently BRCA1 
is associated with the promoter regions and interestingly 
a significant fraction of BRCA1 is associated with 
intergenic spacers (IGS), which contain a number of 
cryptic promoters and regulatory sequences in addition 
to various repetitive sequences (i.e. Alu repeats). 
Notably, IGS is not transcribed by Pol-I, but it is a source 
of a number of non-coding regulatory RNAs (ncRNAs) 
transcribed by Pol-II which may be responsible for 
BRCA1 loading to IGS. Importantly these ncRNAs play 
an essential role in maintaining the chromatin structure 
of rDNA repeats and the nucleolus [31, 32]. 
The level of BRCA1 at the transcribed region 
is lower, but still significant. Therefore, our results 
demonstrate that BRCA1 is present at the entire rDNA 
repeat (~43 kB), but the occupancy at different regions is 
not uniform (Pol-I distribution profile in different cell lines 
is shown in Figure 1C). 
Normally, BRCA1 is preferentially associated 
with promoters, 5′UTR’s and exons and significantly 
underrepresented within introns and intergenic regions 
[27, 28, 30]. Thus, the BRCA1 distribution profile at 
rDNA repeat is different from typical BRCA1 profile at the 
other genomic loci. This suggests that BRCA1 fractions 
associated with different regions of rRNA repeat may 
play distinct roles which depend not only on the specific 
region but also on rDNA chromatin structure which is 
not uniform. More than 300 copies of rDNA repeats are 
present in human cells and recent studies have revealed 
that there are three different states of rDNA chromatin: 
silent, heterochromatic rDNA; poised, transcriptionally 
competent euchromatic rDNA; and active, transcribed 
euchromatic rDNA [31, 33, 34]. Results of our sequential-
ChIP experiment show that BRCA1 associated only 
with the promoter of euchromatic repeats (Figure 1D) 
suggesting that BRCA1 found elsewhere is not involved 
in transcriptional regulation. Notably, the inhibition of 
Pol-I transcription by Pol-I inhibitor 9HE [35] lead to 
selective dissociation of BRCA1 from the promoter 
(without significant changes in BRCA1 occupancy at the 
transcribed region and intergenic spacer) also suggesting 
that association of BRCA1 with promoter region is 
transcription dependent (Figure 1E).
We examined the subcellular distribution of 
endogenous BRCA1 in MCF7, MCF10A and T47D cell 
lines. Immunofluorescence analysis revealed that a small 
fraction of BRCA1 resides in the nucleoli, and co-localises 
with Pol-I subunit RPA135 (Supplementary Figure S2A). 
A significant fraction of BRCA1 is nevertheless localized 
in the nucleoplasm as it was described elsewhere [36, 37]. 
Western blot analysis of cytoplasmic and nucleolar 
fractions showed that presence of BRCA1 in cytoplasm 
is limited (Supplementary Figure S2B) which is in 
agreement with the existing data suggesting that BRCA1 
cytoplasmic fraction is only increased as result of DNA 
damage [38–40].
BRCA1 is not involved in the transcriptional 
regulation of selected ribosome biogenesis 
related genes 
Regulation of ribosome biogenesis requires 
coordination of transcription by all three nucleolar 
polymerases and expression of certain genes. There are 
examples of proteins (e.g. mTOR) and transcription factors 
(e.g. C-MYC) which play roles of master coordinators 
of different stages of ribosome biogenesis [41, 42, 43]. 
BRCA1 too can affect ribosome biogenesis by regulating 
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transcription of different ribosome components (rRNA, 
ribosomal proteins) and/or regulatory factors (i.e. 
components of signalling pathways affecting ribosome 
biogenesis). It has been shown that BRCA1 is involved 
in the regulation of at least one component of a ribosome, 
5S rRNA [22] and here we show that BRCA1 is involved 
in the regulation of the synthesis of large rRNAs by 
Pol-I. Interestingly, the genome wide analysis of BRCA1 
binding sites [29] has revealed that at least three genes 
involved in ribosome biogenesis can be regulated by 
BRCA1 (Table 1), as it has been found at the promoter 
area of these genes. To further investigate this, T47D 
cells were treated with BRCA1 siRNA and HCC1937 
cells were transfected with wt BRCA1, and RNA was 
extracted and converted to cDNA. Expression levels of 
genes in question were analysed by qPCR. A specific 
signal was normalised to the signal of housekeeping gene 
GAPDH and fold of activation or downregulation was 
determined as ratio between normalised expression level 
found in treated and the level found in untreated cells. 
Analysis of the results showed no significant activation 
or downregulation of expression levels of any of these 
genes (Table 1). These results suggest that BRCA1 is 
not involved in the transcriptional regulation of genes 
Figure 1: BRCA1 is associated with rDNA repeat. (A) A diagram of the human rDNA repeat. The positions of eight sets of 
specific PCR primer/probes used for qPCR analysis of immunoprecipitated DNA are indicated. 5′ETS – 5′-external transcribed spacer; 
IGS – intergenic spacer; Prom – the rRNA promoter, term – the terminator. Signal representing the transcribed region (TrR) is the average 
of the combined signal from 5′ETS, 18 S, 5.8 S and 28 S rRNA. Signal representing the non-transcribed region (nTrR) is the average of 
the combined signal from IGS1 and IGS2. (B) ChIP assays were performed using antibodies specific to human BRCA1 and analysed by 
qPCR using eight sets of specific probes and primers derived from different regions of rDNA repeats (see the diagram above). Internal 
standards were used for absolute quantification of immunoprecipitated DNA and chromatin input. The value of each bar represents the 
difference between the signals from the specific antibody and from the negative control (an appropriate IgG) expressed as % from total 
chromatin input. Signal representing the transcribed region (TrR) is the average of the combined signal from 5′ETS, 18 S, 5.8 S and 28 S 
rRNA. Signal representing the non-transcribed region (nTrR) is the average of the combined signal from IGS1 and IGS2. The standard 
deviations from three independent experiments are shown; n = 3 (See also Supplementary Figure S8 for raw data). (C) ChIP assays were 
performed using antibodies specific to the second largest subunit (A135) of human Pol-I and analysed as in B. The standard deviations 
from three independent experiments are shown; n = 3. (D) Chromatin isolated from untreated MCF7 subjected for the first round of 
immunoprecipitation using antibody specific to Pol-I subunit A135. After elution chromatin was subjected to the second IP round using 
antibody specific to human BRCA1 and analysed by qPCR as in B. The standard deviations from three independent experiments are shown; 
n = 3. (E) Cells were treated by 5 µM 9HE (Pol I inhibitor) for 1 hour and ChIP assays were performed using antibodies specific to human 
BRCA1 and analysed as in B. The standard deviations from three independent experiments are shown; n = 3. 
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in question and therefore, cannot be seen as a general 
coordinator of ribosome biogenesis.
BRCA1 interacts with Pol-I transcription 
machinery
BRCA1 interacts with a vast array of proteins 
forming a variety of different protein complexes with 
distinct functionality including CTD domain of Pol-II 
[44] and Pol-III transcription factors Brf1 and Brf2 [22]. 
One of the known complexes containing BRCA1 is the 
RNA polymerase II (Pol-II) holoenzyme [45, 46]. This is 
very large (several MDa) multi-subunit protein complex 
containing all factors necessary for transcription initiation. 
The existence of Pol-I holoenzyme has also been suggested 
previously [47–49] and we performed gel-exclusion 
chromatography of a nuclease treated T47D nuclear 
extract using Superose 6 column (exclusion limit over 
5 MDa) and analysed a void fraction (containing very high 
molecular weight protein complexes) by Western blotting. 
Interestingly, we have detected the presence of BRCA1 
and the basal components of Pol-I transcription apparatus 
(Pol-I, SL1 and UBF) (Supplementary Figure S3). 
Next we tested whether BRCA1 interacted 
with the Pol-I transcription factors by performing co-
immunoprecipitation of BRCA1 from nuclease treated 
nuclear extracts of MCF7, MCF10A, ZR751 and T47D 
cell lines. Immunoprecipitated complexes were analysed 
by Western blotting (Figure 2A) and we found that Pol-I, 
UBF and SL1 all co-immunoprecipitated with BRCA1 
in all cell lines, suggesting that BRCA1 either interacts 
independently with several components of Pol-I apparatus 
or it is a part of Pol-I holoenzyme. 
We have analysed the specific activity of these 
immunoprecipitated complexes using in vitro transcription 
assays [50] and found that the complexes were able to 
support specific transcription when supplemented with 
a template containing the Pol-I promoter (Figure 2B) 
suggesting that BRCA1 interacts with active basal 
components of Pol-I apparatus, supporting a holoenzyme 
hypothesis. None the less, further research are required to 
characterise BRCA1 interactions with specific components 
of Pol-I transcription machinery.
BRCA1 positively regulates rRNA synthesis in 
cells
The association of BRCA1 with the basal Pol-I 
machinery and with the rRNA promoter suggest that 
BRCA1 may be involved in the regulation of Pol-I 
transcription, similar to its involvement in the regulation 
of Pol-II and Pol-III transcription [22, 51, 52]. To address 
a potential role of BRCA1 in the regulation of Pol-I 
transcription we analysed the effect of BRCA1 depletion 
and reconstitution on rRNA synthesis.
siRNA mediated depletion of BRCA1 
(Supplementary Figure S4A) led to ~1.8-fold decrease in 
the synthesis level of the 47S rRNA in T47D cells (Figure 
3A, 3B, 3C). The observed effect of BRCA1 depletion 
in MCF7 cells is more modest (~20% decrease) but still 
statistically significant. Importantly, in contrast to the 
regulation of many other genes a relatively small reduction 
in the level of rRNA transcription could have a profound 
effect and maintenance of elevated levels of Pol-I activity 
in cancer cells appears critically important for cancer cell 
survival [13]. Therefore our results suggest that BRCA1 
Table 1: Effect of BRCA1 depletion and reconstitution on expression of four genes involved in 
ribosome biogenesis
Gene Role
Fold Activation
Significance
BRCA1 depletion BRCA1 reconstitution
RPL36A Ribosomal protein 36, a component of the 60S subunit of the ribosome. 1.03 1.3 No
RPL12
Ribosomal protein 12. This protein is 
a component of the 60S subunit of the 
ribosome. It is a member of the L11P 
family of proteins and is found within 
the cytoplasm.
1.01 1.05 No
RPS6KB1
Ribosomal protein belonging to the 
S6 kinase family of serine/theronine 
kinases. The protein is activated in 
response to mTOR pathway leading to 
increased protein synthesis and cell. 
proliferation
0.94 0.79 No
Total RNA extracted from treated and control cells was analysed by real-time qPCR using primers specific for each gene 
including the housekeeper gene GAPDH. Analysis of the qPCR results demonstrated no significant changes (≥ 2 fold) in the 
relative expression levels of four genes in questions (normalised to GAPDH expression level).
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depletion negatively affects rRNA transcription and the 
degree of this effect is different in different cell lines.
To complement these data we next overexpressed 
exogenous wild-type (wt) BRCA1 in HCC1937 cells 
which harbour an inactive mutated form of BRCA1. We 
observed a statistically significant increase in the level 
of 47S rRNA synthesis in cells expressing wt BRCA1 
(Figure 3C, 3D, 3E). Together, all these results suggest 
that BRCA1 positively regulates rRNA synthesis. 
BRCA1 has been shown to be a part of Pol-II 
holoenzyme [45] and to interact with Pol-III transcription 
factors [22]. The functional significance of the BRCA1-
Pol-II interactions is still unclear, but it has been linked 
to the BRCA1 surveillance role [44, 46]. In the Pol-
III system, interactions between BRCA1 and Pol-III 
transcription factors play a negative role and BRCA1 
represses transcription of Pol-III dependent genes. Here, 
we found that BRCA1 has a stimulatory role in Pol-I 
transcription and interacts with the active components 
of Pol-I pre-initiation complex (PIC). Therefore we can 
hypothesise that BRCA1 is a part of Pol-I holoenzyme and 
as such positively affects PIC formation in cycling cells 
and/or PIC stability, thus stimulating rRNA transcription. 
It may also have a specific role in stimulating transcription 
in the context of chromatin regulation. BRCA1 is known 
to interact with chromatin remodelling complexes 
including SWI/SNF (for reviews see: [53, 54]), which is 
known to facilitate Pol-I transcription [55]. 
We have measured specific Pol-I activity in nuclear 
extracts of untreated and BRCA1 depleted cells using 
Figure 2: Active components of Pol-I transcription machinery co-immunoprecipitate with BRCA1. (A) Nuclear extracts 
were prepared from actively growing cells and incubated for 4 hours with BRCA1 antibody covalently linked to magnetic beads. The 
immuno-complexes were washed 4 times by 0.15 M KCl in TM10 buffer and protein complexes were eluted by 8M urea and analysed by 
Western blotting using antibodies specific to BRCA1, human Pol-I largest subunit A190, UBF and TAF163 subunit of SL1. Lane 1 – HeLa 
NE (positive control); Lane 2 − input (nuclear extract); Lane 3 – immunoprecipitated complexes; and Lane 4 − negative control (IgG). 
Positions of prestained molecular weight markers (PageRuller Plus, Fermentas) are indicated. (B) Beads carrying immuno-complexes 
obtained as above were resuspended in transcription mix containing NTP’s, rDNA template and Pol-II /Pol-III inhibitor α-amanitine. 
Transcribed RNA was analysed by S1 nuclease protection assay with a 32P end-labelled DNA oligonucleotide complementary to the first 
40 nucleotides of the 5′end of the 47S rRNA primary transcript. Reaction in lane 1 is negative control (2 µl HeLa NE and no template). 
Reactions in lanes 2, 3, 4, 5, 10, 11, 12 and 13 contain either 10 µl (even numbers) or 2 µl (odd numbers) of nuclear extract isolated from 
different cell lines as indicated. Reactions in lanes 6, 8, 14 and 16 contain BRCA1 immunoprecipitated complexes and reactions in lanes 7, 
9, 15 and 17 contain IgG negative control isolated from different cell lines as indicated.
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linear, chromatin free DNA template (Figure 4). We were 
unable to detect any differences in Pol-I specific activity 
between extracts prepared from BRCA1 expressing and 
BRCA1 depleted cells. These results strongly suggest 
that BRCA1 has no direct role in basal Pol-I transcription 
(in contrast to Pol-III) and supports our hypothesis that 
BRCA1 stimulates rRNA synthesis in cells via interactions 
with other factors (i.e. chromatin remodellers or/and 
chromatin modifying enzymes or transcription activators). 
Presence of BRCA1 at the transcribed region of rDNA 
suggest that it can be also part of elongating Pol-I and play 
a role in transcription-coupled DNA damage response as it 
was suggested for Pol-II [44] .
DNA damage affects BRCA1 association with 
rDNA and with Pol-I transcription machinery
After discovering a positive effect of BRCA1 
on rRNA transcription we next investigated BRCA1 
behaviour at rDNA loci in response to various types of 
DNA damage using a ChIP approach. To determine 
the optimal dosage of Ultra Violet Radiation (UV)
(which causes single-strand breaks) and X-Ray (which 
causes double-strand breaks) radiation we have exposed 
MCF10A cells to different doses and measured the level 
of rRNA synthesis (Supplementary Figure S5). We found 
that 100 J/m2 UV treatment lead to 10-fold decrease in 
Pol-I transcription whereas 50 J/m2 had much more 
modest effect (Supplementary Figure S5B, S5C). Notably, 
a relatively high X-Ray dosage (8 Gy) led to two fold 
decrease in the level of rRNA synthesis (Supplementary 
Figure S5D, S5E). The difference in the effect of UV 
and X-Ray radiation most likely is linked to differences 
in DNA damage pathways activated by different types 
of DNA damage (for reviews see: [56, 57]) which have 
different effect on Pol-I transcription [58]. 
BRCA1 is an integral part of various DNA 
damage response pathways and is directly involved 
in DNA damage repair. In response to DNA damage 
BRCA1 accumulates near the damaged foci forming 
part of various DNA repair complexes [59–61]. BRCA1 
recruitment is a relatively late event in the complex 
formation but it is usually completed within 1 hour 
post-damage [59, 62] . We therefore investigated the 
recruitment of BRCA1 and Pol-I occupancy at rDNA one 
hour after UV (100 J/m2) or X-Ray (6 Gy) treatments 
in different breast cancer cells (Figure 5). In parallel 
experiment we also determined effect of irradiation 
on rRNA synthesis in the same breast cancer cells 
(Supplementary Figure S6). 
We found that UV treatment led to dissociation 
of BRCA1 from rDNA in MCF10A and MCF7 cells 
(Figure 5B, 5D). Pol-I (A135) occupancy also decreased 
following UV treatment (Figure 5A, 5C) which correlates 
with decreasing Pol-I transcription levels (Supplementary 
Figure S6A). 
X-Ray treatment also led to dissociation of BRCA1 
from rDNA in all cases (Figure 5B, 5D), however its effect 
on Pol-I occupancy (Figure 5A, 5C) and rRNA synthesis 
level (Supplementary Figure S6B) was more diverse. 
Pol-I occupancy and rRNA synthesis were decreased 
in MCF10A cells whereas in MCF7 we observed no 
significant changes in Pol-I occupancy and in rRNA 
synthesis levels. These data suggest that UV treatment 
leads to dissociation of Pol-I complexes from rDNA and 
consequently to significant decreases in transcription 
levels. In contrast, X-Ray treatment leads to the formation 
of stalled Pol-I complexes (and as a result much smaller 
changes in Pol-I occupancy) followed by relatively rapid 
restoration of Pol-I transcription as described earlier 
[58]. It can be hypothesised that rate of displacement 
of stalled Pol-I complexes and consequently restoration 
of transcription is different in different cells which may 
explain differences observed between MCF10A and 
MCF7 cells. 
We have shown that BRCA1 co-immunoprecipitates 
with active Pol-I transcription factors from nuclear 
extracts of untreated breast cancer cells. We next tested 
if the interactions between BRCA1 and Pol-I machinery 
were affected by DNA damage by performing BRCA1 
imunoprecipitation from nuclear extracts prepared from 
breast cancer cells one hour after UV (100 J/m2) or X-Ray 
(6 Gy) treatments. We found that the interactions between 
BRCA1 and the Pol-I transcription machinery were 
disrupted and Pol-I factors no longer co-immunoprecipitated 
with BRCA1 (Figure 6A, 6B).
DISCUSSION
BRCA1 is a known tumour suppressor whose 
main function is to maintain genomic integrity via its 
critical role in DNA damage repair (for latest review 
see: [63]) and involvement in the control of a number of 
fundamental cellular processes such as cell cycle control, 
transcription, chromatin structure and apoptosis [18–21]. 
Loss of BRCA1 leads to genomic instability, but the effect 
of BRCA1 depletion on cell proliferation is more complex 
and may be positive [64, 65] or negative [66, 67] which is 
most likely linked to expression of other proteins, or cell 
type specificities. 
In our hands depletion of BRCA1 in all cell 
lines tested has a negative effect on proliferation 
(Supplementary Figure S7). We also found that 
depletion of BRCA1 led to downregulation of rRNA 
transcription (Figure 3A–3C) whereas introduction of 
BRCA1 has an opposite effect (Figure 3D–3F). This is 
interesting and unexpected finding because majority of 
tumour suppressors involved in the regulation of rRNA 
synthesis including p53, ARF, Rb and PTEN are known 
to have inhibitory effect (for latest reviews see [10, 68]). 
Furthermore, BRCA1 is shown to repress Pol-III directed 
transcription [22], thus negatively affecting ribosome 
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Figure 3: BRCA1 positively regulates rRNA synthesis in cells. (A) Schematic representation of the labelling of cells with 
3H-uridine to determine the effect of BRCA1 depletion on ongoing rRNA synthesis. (B) RNA was extracted 4 hours after 3H-uridine 
addition and de novo rRNA transcripts were detected by tritium imaging of RNA blots (top panel). Total 18 S and 28 S rRNAs were detected 
by ethidium bromide staining (bottom panel). (C) To determine the relative efficiencies of rRNA synthesis, RNA blots were imaged 
using tritium image plate (Fuji) and quantitated with the aid of phosphoimager (Fuji) and Aida software (Raytec). Transcript levels are 
indicated for 47 S pre-rRNA. The data are expressed as a percentage of the highest value (set at 100%). Standard deviations and statistical 
significance are shown; ***p < 0.001. P-values have been calculated using one and two-way ANOVA on R software; n = 3. (D) Schematic 
representation of the labelling of cells with 3H-uridine to determine the effect of BRCA1 reconstitution on ongoing rRNA synthesis. 
HCC1937 cells expressing inactive BRCA1 mutant were transfected by construct carrying wt BRCA1. 3H-uridine was added 48 hours post-
ransfection. (E) RNA was extracted 1 and 2 hours after 3H-uridine addition and de novo rRNA transcripts were detected by tritium imaging 
of RNA blots (top panel). Total 18 S and 28 S rRNAs were detected by ethidium bromide staining (bottom panel). (F) To determine the 
relative efficiencies of rRNA synthesis, RNA blots were imaged using tritium image plate (Fuji) and quantitated with aid of phosphoimager 
(Fuji) and Aida software (Raytec). Transcript levels are indicated for 47 S pre-rRNA. The data are expressed as a percentage of the highest 
value (set at 100%); Standard deviations and statistical significance are shown; ***p < 0.001; P-values have been calculated using one and 
two-way ANOVA on R software; n = 3.
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biogenesis (requiring 5S rRNA and U6 snRNA) and 
protein biosynthesis (requiring tRNAs). Therefore, we 
observe an apparent paradox between BRCA1 tumour 
suppressor role and its functions in Pol-I transcription. 
BRCA1 is known to act as a co-activator/co-
repressor and its role in regulating Pol-II dependent 
transcription in general is heavily dependent on its 
ability to recruit specific transcription factors to relevant 
promoters. A prime example of this could be the well 
characterised relationship between BRCA1 and C-MYC, 
whereby BRCA1 requires C-MYC for recruitment to key 
target promoters such as hTERT/telomerase [69, 70]. 
Our colleagues (including several co-authors on this 
manuscript) have shown that S100 proteins are C-MYC/
BRCA1 co-regulated genes in which BRCA1 represses 
transcription through a C-MYC dependent mechanism 
and expression of these proteins, most notably S100A7, 
is strongly upregulated in BRCA1 mutant breast cancer 
cells [71]. It is well known that C-MYC has an important 
role in the control of ribosome biogenesis (reviewed in 
[43]). We propose, in this context that BRCA1 participates 
in coordinated co-activation of rRNA gene transcription 
through transcription factors such as C-MYC (and 
potentially multiple others) probably as a part of Pol-I 
holoenzyme complex. The role of BRCA1 in Pol-
III transcription could be different and better aligned 
with classical functions of tumour suppressor targeting 
expression of oncogenes. 
Importantly, our findings that basal components 
of Pol-I transcription machinery co-immunoprecipitate 
and co-elute with BRCA1 supports this hypothesis. 
Furthermore, like many BRCA1 interactors, this 
BRCA1/C-MYC interaction could potentially be altered 
following BRCA1/Pol-I encountering DNA damage in 
rDNA. Our observation that interactions of BRCA1 with 
Pol-I transcription machinery are abolished following 
DNA damage, supports this hypothesis. In these cases 
it would be logical to predict that BRCA1 would help 
stall or remove Pol-I from rDNA promoters to facilitate 
entry of DNA repair complexes into the damaged region 
and prevent aberrant transcription. The co-ordinated 
activation controlled by BRCA1/C-MYC could also go 
awry in instances of BRCA1 dysfunction (such as in cases 
of mutation/epigenetic downregulation), resulting in the 
Figure 4: Specific activity of basal Pol-I transcription machinery is not affected by BRCA1 depletion. (A) Nuclear extracts 
were prepared from actively growing T47D cells transfected either with scr siRNA or BRCA1 specific siRNA. Specific transcription 
efficiencies were determined using different quantities of nuclear extracts supplemented with NTP’s and rDNA template. Transcribed RNA 
were analysed by S1 nuclease protection assay with a 32P end-labelled DNA oligonucleotide complementary to the first 40 nucleotides of 
the 5′end of the 47 S rRNA primary transcript. Left panel – cells treated with scr siRNA, Lanes 1, 2 and 3 contains 10, 20 and 40 µg of total 
protein respectively; Righ panel – cells treated with BRCA1 specific siRNA, Lanes 1, 2 and 3 contains 10, 20 and 40 µg of total protein 
respectively. (B) To determine the relative specific activity signals from panels above were quantitated with aid of phosphoimager (Fuji) 
and Aida software (Raytec). The data are expressed as a percentage of the highest value (set at 100%); the standard deviations for three 
independent experiments are shown; n = 3.
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Figure 5: BRCA1 and Pol I association with rDNA affected by DNA damage. (A–D) ChIP assays were performed from 
chromatin isolated from either UV (100 J/cm2) or X-Ray (6 Gy) treated or untreated MCF10A and MCF7 cells using antibodies specific 
either to A135 (A and C) or to human BRCA1 (B and D) as indicated. ChIP DNA was analysed by qPCR. Internal standards were used 
for absolute quantification of immunoprecipitated DNA and chromatin input. The value of each bar represents the difference between 
the signals from the specific antibody and from the negative control (an appropriate IgG) expressed as % from total chromatin input. 
Signal representing the transcribed region (TrR) is the average of the combined signal from 5′ETS, 18 S, 5.8 S and 28 S rRNA. Signal 
representing the non-transcribed region (nTrR) is the average of the combined signal from IGS1 and IGS2. The standard deviations from 
three independent experiments are shown; n = 3.
Figure 6: BRCA1 interactions with Pol-I transcriptional machinery affected by DNA damage. (A–B) E. Nuclear extracts 
were prepared from either UV (100 J/m2) or X-Ray (6 Gy) treated cells as indicated. Immuno-precipitation and analysis were performed as 
in Figure 2A. Lanes 1, 4 − input (nuclear extract). Lanes 2, 5 − immunoprecipitation, lanes 3, 6 − IgG negative control and lanes 7 − purified 
SL1. Positions of prestained molecular weight markers (PageRuller Plus, Fermentas) are indicated.
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uncontrolled (C-MYC driven) transcriptional activation of 
rRNA genes. 
Notably, our discovery of BRCA1 interaction with 
Pol-I machinery is reminiscent of the well described 
analogous roles for BRCA1 in Transcription Coupled 
Repair [61, 72]. It is possible that BRCA1 could reside 
in a complex with Pol-I at rDNA promoters with 
elongating Pol-I facilitating Pol-I transcription, and in 
return association with Pol-I would provide BRCA1 with 
an opportunity to monitor actively transcribed rDNA 
for DNA damage, including abasic sites, double-strand 
breaks, intra-strand thymine dimers and inter-strand cross 
links. Interestingly, different types of DNA damage have 
different effects on the association of Pol-I with rDNA 
(Figure 5A, 5C), but similar effects on BRCA1 occupancy 
(Figure 5B, 5D). This is most likely the consequence 
of activation of different signalling pathways which 
either cause rapid dissociation of Pol-I (UV treatment) 
or accumulation of stalled Pol-I complexes (X-Ray) as 
described earlier [58]. However, in both cases interactions 
of BRCA1 with Pol-I machinery are weakened (Figure 6) 
resulting rapid dissociation of BRCA1 from rDNA.
Therefore, interactions of BRCA1 with active Pol-I 
machinery facilitate a specific targeting of BRCA1 to 
transcriptionally active rDNA which lead to preferential 
repair of these rDNA at the expense of non-transcribed 
repeats. Given large number of transcriptionally inactive 
rDNA repeats (~150–300 repeats per human genome) and 
length of rRNA gene (~13 kB) this would be especially 
pertinent. Thus, we propose that stimulatory role of 
BRCA1 in rRNA transcription is the consequence of 
BRCA1 surveillance role in rDNA repair.
MATERIALS AND METHODS
Tissue culture
MCF7, MCF10A, T47D, ZR751 and HCC1937 cells 
were obtained from ATCC and maintained according to 
the supplier’s instructions and as described elsewhere. 
All media were supplemented with 10% FBS (PAA) and 
100 U/ml penicillin and 100 µg/ml streptomycin (Gibco). 
All cells were grown in 37°C incubator at 5% CO2.
Transfections
T47D cells were allowed to grow to a density 
of 60%. Growth media was removed and replaced 
with fresh media. A double transfection with 15 nM 
siRNA (Invitrogen) added 24 hours apart was carried 
out using RNAi max reagent (Invitrogen) according to 
manufacturer instructions. Cells were allowed to grow 48 
hours postransfection before RNA isolation or metabolic 
labelling experiments. 
Human breast cancer cell line HCC1937 containing 
germ line mutation in BRCA1 was grown to a density 
of 70% and transfected with pCDNA3.1 expression 
plasmid containing wild type BRCA1 or an empty vector 
using Genejuice (Roche) transfection reagent following 
manufacturer’s instructions in Optimem media. The 
cells were left 36-72 hours posttransfection before RNA 
isolation metabolic labelling experiments. 
Antibodies
All antibodies are described in Supplementary 
Table S1.
Immunocytochemistry 
Cells were grown up to ~70% confluency (~50% for 
starved/re-fed experiments) and were fixed for 10 minutes 
with 4% paraformaldehyde, permeabilized for 10 min with 
1% Triton X-100 and blocked for 10 min with 1% donkey 
serum in PBS. Cells were then incubated with appropriate 
antibodies in the blocking buffer (0.1% donkey serum 
in PBS) for 1 hour, washed 3 × 10 min in PBS and 
incubated with labelled secondary antibodies for 1 hour. 
After washes the cells were mounted on a glass slide with 
Vectashield containing DAPI and visualised using a Leica 
TCS SP5 confocal microscope.
Chromatin immunoprecipitation (ChIP) assay
ChIPs were performed essentially as described 
previously [35, 73]. Briefly, cells were grown until 
~70% confluent, cross-linked with formaldehyde (final 
concentration 1%) for 10 min and the cross-linking 
was stopped by addition of glycine (final concentration 
0.125 M) for 5 min. Crosslinked chromatin was isolated 
as described previously [74] and was sheared to 
250-base-pair average size. Immunopreciptations were 
carried out using chromatin isolated from 1 × 106 or 2.5 
× 105 cells and appropriate antibodies. 
Purified DNA was analysed by qPCR using 
QuantiFast Multiplex PCR Mix (Qiagen) and two sets (I 
and II) of four and three primer combinations and probes, 
which covers different regions of rDNA repeat on Light 
Cycler 480-II (Roche). PCR parameters and reactions 
were set as recommended by the PCR Mix manufacturer 
(Qiagen) and were performed in triplicates, with the 
standard deviation calculated from three independent 
ChIP experiments. Results were expressed as percentage 
of input chromatin and normalized to control IgG levels.
Immunoprecipitation and immunoblotting 
M280 Sheep-anti Mouse beads (Invitrogen) 
were were washed three times with 0.005% Tween-
PBS (PBST). Beads were then incubated with BRCA1 
antibody or mouse IgG as a negative control (50 µl:5 µg) 
for one hour at room temperature followed by 30 minute 
incubation at room temperature with 5 mg/ml DMP 
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(Pierce) in 0.1 M Borate buffer, pH8.2. The crosslinker 
is removed and 1 ml 0.1 M Tris-HCL, pH 7.9 was added 
for 15 minutes. The beads were incubated overnight with 
200 µl PBS/0.1%BSA at 4oC. The beads were then washed 
twice with PBST and twice with 0.1 M KCl in TM10i 
(TM10i buffer: 50 mM Tris-HCl pH 7.9, 12.5 mM MgCl2, 
1 mM EDTA, 10% glycerol). 
50 µl nuclear extract (5 – 25 mg/ml total protein 
concentration) prepared as described previously [75] was 
incubated with 50 µl pre-blocked, crosslinked beads for 
4 hours at 4oC. The beads were then placed on a magnet 
and washed 3 times with 0.1 M KCl in TM10 i buffer 
and eluted twice, once with 15 µl 8 M Urea followed 
by 15 µl 2× LDS loading buffer at 37oC for 15 minutes. 
Eluted proteins were analysed by immunoblotting using 
various antibodies listed above. The TM10 i buffer was 
supplemented with EDTA-free complete protease inhibitor 
cocktail (Roche) and Phosphatase Inhibitor Cocktail 2 
(Calbiochem).
In vivo RNA labelling and rRNA analysis
In vivo labelling of RNA from cells (60–70% 
confluent), was performed essentially as described [76], 
using 10 μCi 3H-uridine for ~0.2–0.4 × 105 cells per well 
of a 6-well plate. In pulse-chase labelling, cells were 
incubated for 2 h with 3H-uridine, washed and incubated 
in unlabeled medium containing 0.5 mM uridine. RNA 
was extracted using Ambion PureLink RNA kit. 2 µg of 
3H-labelled total RNA was run on a 1% formaldehyde 
agarose gel at 120 V for 90 min in 1× MOPS running 
buffer, blotted onto Hybond-N membrane (Amersham), 
cross-linked (UV-crosslinker, UVP) and analysed by 
tritium imaging using a Fuji Tritium image plate (or 
following Perkin-Elmer En3Hance spray, exposed to 
Kodak Biomax XAR film at –80ºC), then quantified using 
Aida software. The standard deviation was calculated from 
three independent experiments.
UV and X-Ray treatments
Cells were grown in normal growth medium 
overnight. They were then subjected to 9.9 J/m2 in UV 
crosslinker (UVP) and allowed to grow for 1 hour before 
harvesting or metabolic labelling experiments.
Cells were grown in normal growth medium 
overnight. They were then subjected to X-Ray treatment 
of 4 Gy, 6 Gy and 8 Gy. The cells were allowed to grow 
for 1 hour before harvesting or metabolic labelling 
experiments.
Gene expression analysis
RNA from transfected and control cells was purified 
using the Ambion PureLink RNA kit following the 
manufacturer’s instructions and the RNA concentration 
was determined spectroscopically. 1 µg of RNA was 
converted to cDNA using the High Capacity RNA-to-
cDNA reverse transcriptase kit (Applied Biosystems). 
Pol-II transcripts were analysed on the LighCycler 
480 thermocycler (Roche) using the Custom gene plate 
(Roche) according to manufacturer instruction. 
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